Mechanistic description
Serotonergic dysfunction precedes motor symptoms in PD; 5-HT1A/1B agonism proposed to reduce neuroinflammation. Despite high druggability, the mechanism lacks human causal validation and carries extensive clinical failure history including sarizotan, with no interventional evidence demonstrating cytokine modulation in CNS.
Mechanism / pathway
- SLC6A4 (SERT), HTR1A, HTR1B
- neurodegeneration
Evidence for (3)
Raphe serotonergic neuron loss observed in prodromal PD via SPECT imaging
5-HT1A agonists reduce dyskinesia in animal models
Existing chemical matter (buspirone, tandospirone) is brain-penetrant
Evidence against (3)
Sarizotan (5-HT1A agonist) failed Phase II for levodopa-induced dyskinesia
Serotonergic lesioning in animals does not reliably produce α-syn pathology
Human serotonergic drugs show minimal cytokine modulation in CNS
Evidence matrix
Supporting
- Raphe serotonergic neuron loss observed in prodromal PD via SPECT imaging PMID:15731597
- 5-HT1A agonists reduce dyskinesia in animal models PMID:16707720
- Existing chemical matter (buspirone, tandospirone) is brain-penetrant PMID:Multiple pharmacology references
Contradicting
- Sarizotan (5-HT1A agonist) failed Phase II for levodopa-induced dyskinesia PMID:19649756
- Serotonergic lesioning in animals does not reliably produce α-syn pathology PMID:Negative preclinical studies
- Human serotonergic drugs show minimal cytokine modulation in CNS PMID:16597621
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Serotonergic 5-HT1A/1B Agonism for Neuroprotection. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-6d75f21bc9
@misc{scidex_hypothesis_h6d75f21,
title = {Serotonergic 5-HT1A/1B Agonism for Neuroprotection},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-6d75f21bc9},
note = {SciDEX artifact hypothesis:h-6d75f21bc9}
}